143 related articles for article (PubMed ID: 21954818)
1. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
4. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
6. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
8. [Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of secondary hypertension].
Hertig A
Rev Prat; 2010 May; 60(5):644-5, 647-8. PubMed ID: 20564846
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review.
Boehm S; Rothermundt C; Hess D; Joerger M
Gerontology; 2010; 56(3):303-9. PubMed ID: 19940466
[TBL] [Abstract][Full Text] [Related]
10. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
11. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
12. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
13. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
Kakeya H; Osada H
Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. VEGF-targeted therapy: mechanisms of anti-tumour activity.
Ellis LM; Hicklin DJ
Nat Rev Cancer; 2008 Aug; 8(8):579-91. PubMed ID: 18596824
[TBL] [Abstract][Full Text] [Related]
17. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
18. Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG; Elisaf MS
Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
20. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
Steeghs N; Gelderblom H; Roodt JO; Christensen O; Rajagopalan P; Hovens M; Putter H; Rabelink TJ; de Koning E
Clin Cancer Res; 2008 Jun; 14(11):3470-6. PubMed ID: 18519779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]